We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

MRI Scans Used Alongside PSA Test Detect Prostate Cancer Missed by Blood Test

By MedImaging International staff writers
Posted on 24 Aug 2023

Typically, men aged over 50 opt for a prostate-specific antigen (PSA) test when experiencing symptoms or concerns related to prostate cancer. PSA, a protein produced by both normal and cancerous prostate cells, can indicate potential prostate issues, including cancer when its levels are elevated. Now, new research reveals that MRI when used as a screening test in conjunction with the PSA test can detect prostate cancer that is likely to be missed by the blood test alone.

The REIMAGINE study that included researchers from King’s College London (London, UK) is the first study to utilize MRI scans alongside PSA density to evaluate the requirement for additional standard NHS tests. Among the 48 participants identified with significant prostate cancer, half exhibited a 'low' PSA score, a threshold that would not prompt further investigation under the present system. The study invited men aged 50 to 75 for both a screening MRI and a PSA test.


Image: MRI scans have been shown to improve prostate cancer diagnosis in screening trials (Photo courtesy of Freepik)
Image: MRI scans have been shown to improve prostate cancer diagnosis in screening trials (Photo courtesy of Freepik)

Among the 303 men who underwent both tests, 48 (16%) displayed a positive result on the screening MRI indicating cancer, despite having a median PSA density of 1.2 ng/ml. Two-thirds of these individuals had PSA levels below the current screening benchmark of 3 ng/ml, meaning they would not have been referred for further examination based on the current PSA test protocol. Following NHS assessment, 29 men (9.6%) were diagnosed with cancer necessitating treatment, and three men (1%) were diagnosed with low-risk cancer not requiring treatment.

“The thought that half the men with clinically significant cancer had a PSA less than 3 ng/ml and would have been reassured that they didn’t have cancer by a PSA test alone is a sobering one and reiterates the need to consider a new approach to prostate cancer screening,” said Professor Caroline Moore (UCL Surgical & Interventional Science and consultant surgeon at UCLH), chief investigator of the study and NIHR Research Professor. “Our results give an early indication that MRI could offer a more reliable method of detecting potentially serious cancers early, with the added benefit that less than one percent of participants were ‘over-diagnosed’ with low-risk disease. More studies in larger groups are needed to assess this further.”

Related Links:
King’s College London


Mammo DR Retrofit Solution
DR Retrofit Mammography
New
Radiology Monitor
Barco MDNC-12130 Nio Fusion 12MP Radiology Monitor
Digital Radiography System
DR-300
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+

Latest MRI News

Cardiac MRI Detects Hidden Heart Dysfunction After Heart Attack
24 Aug 2023  |   MRI

AI Tool Reveals Cortical Lesions on Standard MRI in Multiple Sclerosis
24 Aug 2023  |   MRI

AI Reconstruction Tool Speeds Dynamic Breast MRI and Improves Cancer Detection
24 Aug 2023  |   MRI